Description
Sotorasib is a inhibitor of KRASG12C, which is a notoriously difficult to treat cancerous mutation.
Sotorasib
Product ID S584778
Cas No. 2296729-00-3
Purity ≥99%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 2296729-00-3 |
|---|---|
| Purity | ≥99% |
| Formula | C30H30F2N6O3 |
| Formula Wt. | 560.61 |
| IUPAC Name | (1R)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]-pyrido[2,3-d]pyrimidin-2(1H)-one |
| Synonym | AMG-510 |
| Appearance | White powder |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| Info Sheet |
|---|
References
Zheng X, Luo J, Liu W, et al. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12c mutation. Drugs Today (Barc). 2022 Apr;58(4):175-185. PMID: 35412531
Werner J, Davies R, Wahlstrom J, et al. Mercapturate pathway metabolites of sotorasib, a covalent inhibitor of KRASG12c, are associated with renal toxicity in the Sprague Dawley rat. Toxicol Appl Pharmacol. 2021 Jul 15;423:115578. PMID: 34004237
Koga T, Suda K, Fujino T, et al. KRAS secondary mutations that confer acquired resistance to KRAS G12c inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments. J Thorac Oncol. 2021 Aug;16(8):1321-1332. PMID: 33971321